Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SD Bylvay Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.42

    Bylvay (odevixibat) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.42 alerts

    Get alerted when Policy 05.04.42 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Bylvay (odevixibat) to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC) or cholestatic pruritus associated with Alagille syndrome (ALGS), subject to clinical criteria, documentation, specialist involvement, exclusions, and dosing limits.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyBylvay (odevixibat) Coverage Criteria
    Policy CodePolicy 05.04.42
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable diagnosis and clinical criteria for initial requests, or benefit from therapy for continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered indications
    6 monthsInitial authorization
    12 monthsContinuation authorization
    3 monthsMinimum PFIC age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsMinimum ALGS age
    4Quantity-limit formulations

    Coverage Criteria

    Initial Therapy: PFIC

    Covered for PFIC-associated pruritus when all of the following are met:

    PFIC initial therapy

    • Confirmed molecular PFIC diagnosis: Member has a confirmed molecular diagnosis of PFIC, such as ATP8B1, ABCB11, ABCB4, TJP2, or MYO5B gene variants.
    • Evidence of cholestasis: Member has evidence of cholestasis, such as an elevated serum bile acid level.
    • No other concomitant liver disease: Member does not have any other concomitant liver disease, such as biliary atresia, liver cancer, or an alternate non-PFIC-related etiology of cholestasis.
    • No prior liver transplant: Member has not received a liver transplant.
    • Minimum age: Member is 3 months of age or older.>= 3 months

    Initial Therapy: ALGS

    Covered for ALGS-associated cholestatic pruritus when all of the following are met:

    ALGS initial therapy

    • ONE of the following accepted ALGS diagnosis pathways

      • Genetic diagnosis: Genetic testing shows a JAG1 or NOTCH2 gene variant.
      • Family history plus clinical feature: Member has a family history of ALGS and one or more major clinical features of ALGS.
      • Bile duct paucity plus clinical features: Member has bile duct paucity and three or more major clinical features of ALGS.3 or more major features

    Continuation Therapy

    Continuation therapy is covered when the member is experiencing benefit from therapy:

    Continuation benefit: Member is experiencing benefit from Bylvay therapy, such as improvement in pruritus.

    Authorization may be granted for 12 months, including for new members requesting continuation of therapy.

    Coverage will not be provided for members with PFIC type 2 caused by variants in the ABCB11 gene that result in a non-functional or completely absent bile salt export pump (BSEP) protein.

    Coverage will not be provided for members with prior or active hepatic decompensation, including events such as variceal hemorrhage, ascites, or hepatic encephalopathy.

    Bylvay must not be used concomitantly with another ileal bile acid transporter (IBAT) inhibitor, such as Livmarli.

    Bylvay is considered not medically necessary when the member does not meet the coverage criteria established in this policy.

    Coding and Clinical Requirements

    Procedures and Billing Codesmixed
    N/ANot applicable (N/A)
    Procedures and Billing Codesmixed
    N/ANot applicable (N/A)
    Evidence of cholestasis
    RequirementEvidence of cholestasis
    ExampleElevated serum bile acid level
    Applies toPFIC and ALGS coverage criteria
    Minimum age for PFIC
    Minimum age3 months
    Applies toPFIC-associated pruritus
    Authorization period6 months may be granted when all criteria are met

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Bylvay (odevixibat) initial and continuation requests. Submit the applicable diagnosis and supporting clinical documentation demonstrating that the requested therapy meets the coverage criteria.

    Documentation Required

    Required Clinical Documentation

    Provide the required clinical documentation with the prior authorization request. Initial requests require genetic testing results confirming PFIC or ALGS, if applicable; continuation requests require chart notes or medical-record documentation showing benefit from therapy, such as improvement in pruritus.

    • Initial requests: Genetic testing results confirming PFIC or ALGS, if applicable.
    • Continuation requests: Chart notes or medical-record documentation showing benefit from therapy, such as improvement in pruritus.

    Background

    Bylvay (odevixibat) is used to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and cholestatic pruritus associated with Alagille syndrome (ALGS). Coverage is subject to clinical eligibility requirements, supporting documentation, specialist prescribing or consultation, and applicable exclusions. The policy excludes certain severe or alternate hepatic conditions, including PFIC type 2 with non-functional or absent BSEP protein, hepatic decompensation, and concomitant treatment with another IBAT inhibitor.

    Definitions

    BSEP
    TermBSEP
    Full nameBile salt export pump
    Encoded byABCB11 gene
    IBAT inhibitor
    TermIBAT inhibitor
    IBAT meansIleal bile acid transporter
    ExampleLivmarli

    Initial Therapy

    Initial Therapy: PFIC

    Authorization of 6 months may be granted for PFIC-associated pruritus when all of the following criteria are met:

    PFIC initial therapy

    • Confirmed molecular PFIC diagnosis: Member has a confirmed molecular diagnosis of PFIC, such as ATP8B1, ABCB11, ABCB4, TJP2, or MYO5B gene variants.
    • Evidence of cholestasis: Member has evidence of cholestasis, such as an elevated serum bile acid level.
    • No other concomitant liver disease: Member does not have any other concomitant liver disease, such as biliary atresia, liver cancer, or an alternate non-PFIC-related etiology of cholestasis.

    Continuation Therapy

    Continuation Therapy

    Authorization of 12 months may be granted for all members, including new members, requesting continuation when the member is experiencing benefit from therapy:

    Continuation benefit

    • Clinical benefit: Documentation shows that the member is experiencing benefit from therapy, such as improvement in pruritus.

    Bylvay Quantity Limits

    Quantity limit
    FormulationBylvay 200 mcg oral pellet
    Standard limit360
    Period and unitPer 30 days; oral pellets
    Quantity limit
    FormulationBylvay 400 mcg capsule
    Standard limit540
    Period and unitPer 30 days; capsules
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyBylvay (odevixibat) Coverage Criteria
    Policy CodePolicy 05.04.42
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable diagnosis and clinical criteria for initial requests, or benefit from therapy for continuation requests.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical RequirementsProvider Requirements and Authorization ActionsBackgroundDefinitionsInitial TherapyContinuation TherapyBylvay Quantity Limits
    Clinical features: Member has four or more major clinical features of ALGS.4 or more major features
  1. Evidence of cholestasis: Member has evidence of cholestasis, such as an elevated serum bile acid level.
  2. No other concomitant liver disease: Member does not have a history or presence of other concomitant liver disease, such as biliary atresia, PFIC, or liver cancer.
  3. No prior liver transplant: Member has not received a liver transplant.
  4. Minimum age: Member is 12 months of age or older.>= 12 months
  5. Minimum age for ALGS
    Minimum age12 months
    Applies toALGS-associated cholestatic pruritus
    Authorization period6 months may be granted when all criteria are met
    Note

    Specialist Prescriber or Consultation

    Bylvay must be prescribed by, or used in consultation with, a hepatologist or gastroenterologist.

    Denial Risk

    Excluded Hepatic Conditions

    Coverage is excluded for members with PFIC type 2 caused by ABCB11 variants resulting in a non-functional or completely absent bile salt export pump (BSEP) protein, or with prior or active hepatic decompensation.

    • PFIC type 2 with ABCB11 variants resulting in non-functional or complete absence of BSEP protein.
    • Prior or active hepatic decompensation, including variceal hemorrhage, ascites, or hepatic encephalopathy.
    Denial Risk

    Concomitant IBAT Inhibitor Use

    The member cannot use Bylvay concomitantly with another ileal bile acid transporter (IBAT) inhibitor, such as Livmarli.

    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when required diagnosis, cholestasis, age, transplant, or concomitant liver disease criteria are not met for the requested indication.

    • For PFIC: confirmed molecular diagnosis, evidence of cholestasis, no other concomitant liver disease, no prior liver transplant, and age 3 months or older.
    • For ALGS: an approved diagnostic basis, evidence of cholestasis, no other concomitant liver disease, no prior liver transplant, and age 12 months or older.
    No prior liver transplant:
    Member has not received a liver transplant.
  6. Minimum age: Member is 3 months of age or older.>= 3 months
  7. Initial Therapy: ALGS

    Authorization of 6 months may be granted for ALGS-associated cholestatic pruritus when all of the following criteria are met:

    ALGS initial therapy

    • ONE of the following accepted ALGS diagnosis pathways

      • Genetic diagnosis: Genetic testing shows a JAG1 or NOTCH2 gene variant.
      • Family history plus clinical feature: Member has a family history of ALGS and one or more major clinical features of ALGS.
      • Bile duct paucity plus clinical features: Member has bile duct paucity and three or more major clinical features of ALGS.3 or more major features
      • Clinical features: Member has four or more major clinical features of ALGS.4 or more major features
    • Evidence of cholestasis: Member has evidence of cholestasis, such as an elevated serum bile acid level.
    • No other concomitant liver disease: Member does not have a history or presence of other concomitant liver disease, such as biliary atresia, PFIC, or liver cancer.
    • No prior liver transplant: Member has not received a liver transplant.
    • Minimum age: Member is 12 months of age or older.>= 12 months
    Quantity limit
    FormulationBylvay 600 mcg oral pellet
    Standard limit120
    Period and unitPer 30 days; oral pellets
    Quantity limit
    FormulationBylvay 1200 mcg capsule
    Standard limit180
    Period and unitPer 30 days; capsules
    Standard limit per 30 days
    FormulationBylvay 200 mcg oral pellet
    Standard limit per 30 days360 per 30 days
    Dosage formOral pellets
    Standard limit per 30 days
    FormulationBylvay 400 mcg capsule
    Standard limit per 30 days540 per 30 days
    Dosage formCapsules
    Standard limit per 30 days
    FormulationBylvay 600 mcg oral pellet
    Standard limit per 30 days120 per 30 days
    Dosage formOral pellets
    Standard limit per 30 days
    FormulationBylvay 1200 mcg capsule
    Standard limit per 30 days180 per 30 days
    Dosage formCapsules